Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Close to a year after Seres declared that it had jumped back on track after a troubling setback with its lead microbiome drug for Clostridium difficile infections, a dark horse in the pack is challenging it for the lead in the emerging field.
Four months after merging with Crestovo, Finch Therapeutics has raised $36 million in Series B money to hustle ahead with a mid-stage study of CP101 that got underway last summer. The “full spectrum microbiota” product was the main attraction for the merger, Finch CEO Mark Smith tells me, and replaced their own rival therapy in the pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.